Αρχική World News TP53 Allelic State is Critical in Myelodysplastic Syndromes

TP53 Allelic State is Critical in Myelodysplastic Syndromes

A study performed among 3,324 patients with myelodysplastic syndromes (MDS) with analysis of TP53 mutations and allelic imbalances shows that consideration of TP53 allelic state is critical for diagnostic and prognostic precision in MDS, as well as in future correlative studies of treatment response. The findings are published on 3 August in the Nature Medicine by a group of international researchers. Seishi Ogawa of the Department of Pathology and Tumor Biology, Kyoto University in Kyoto, Japan and Elli Papaemmanuil of the Computational Oncology Service, Department of Epidemiology & Biostatistics, and Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA jointly supervised this work.

The authors wrote in the study background that TP53 is the most frequently mutated gene in cancer. In patients with MDS, TP53 mutations are associated with high-risk disease, rapid transformation to acute myeloid leukaemia, resistance to conventional therapies and dismal outcomes.

Consistent with the tumour suppressive role of TP53, patients harbour both mono- and biallelic mutations. However, the biological and clinical implications of TP53 allelic state have not been fully investigated in MDS.

The study team delineated two subsets of patients with distinct phenotypes and outcomes. One-third of TP53-mutated patients had monoallelic mutations whereas two-thirds had multiple hits (multi-hit) consistent with biallelic targeting.

Established associations with complex karyotype, few co-occurring mutations, high-risk presentation and poor outcomes were specific to multi-hit patients only. TP53 multi-hit state predicted risk of death and leukemic transformation independently of the Revised International Prognostic Scoring System.

Monoallelic patients did not differ from TP53 wild-type patients in outcomes and response to therapy.

The authors concluded that their study shows that TP53 allelic state is critical for diagnostic and prognostic precision in MDS.

Clinical, copy number and mutation data from this work are available here. Databases used in the study are gnomAD, COSMIC, cBioPortal for Cancer Genomics, OncoKB Precision Oncology Knowledge Base, ClinVar and the IARC TP53 Database.

This work was supported in part by grants from the Celgene Corporation through the MDS Foundation. It was also supported by multiple grants to individual investigators.

Reference

Bernard E, Nannya Y, Hasserjian RP, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine; Published online 3 August 2020. DOI: https://doi.org/10.1038/s41591-020-1008-z

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Women Over Age 65 Years with Pathogenic Variants in Cancer Predisposition Genes Continue to Be at Increased Risk of Breast Cancer

Women over age 65 years with pathogenic variants in cancer predisposition genes rarely benefit from hereditary cancer genetic testing. A population-based study examined whether...

Improving cancer care for the LGBTQ+ community

There are approximately 2.3 million people in the UK who identify as part of the lesbian, gay, bisexual, transgender, queer or questioning (LGBTQ+) community...

CancerLand Bookshelf : Loosen

Author: Kyle PotvinISBN: 9781939449078LoosenInformation: Hobblebush Books, 2021 $18.00 USOncolink Rating ⭐️⭐️⭐️ (3/3)Flattered. That’s the best word to describe how I felt last week after...

Scientists developing urine and blood tests to detect brain tumours

Cancer Research UK scientists are developing tests that can detect the presence of glioma, a type of brain tumour, in patient urine or blood...

Foodie Fridays: It’s Cucumber Season!

You never know what will happen when you plant those tiny seeds in early spring. This year did not disappoint when it comes to...

FDA Grants Regular Approval to Pembrolizumab and Lenvatinib for Advanced Endometrial Carcinoma

On 21 July 2021, the US Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) in combination with lenvatinib (Lenvima, Eisai) for patients with...